DeepMed Research

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Phase 1

Terminated

Conditions: Autoimmune Hemolytic Anemia
Failure of Two Rounds of Treatment

Interventions: Drug: Linperlisib

First Posted Date: 2023-01-09

Last Posted Date: 2024-02-07

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 4

Registration Number: NCT05676697

Locations: 🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China
🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China

Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Phase 1

Completed

Conditions: Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Interventions: Drug: Linperlisib

First Posted Date: 2023-01-09

Last Posted Date: 2024-05-29

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 8

Registration Number: NCT05676710

Locations: 🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China
🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China

The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: Ursodeoxycholic acid

First Posted Date: 2022-12-21

Last Posted Date: 2025-02-24

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 95

Registration Number: NCT05659654

Locations: 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital,CAMS & PUMC, Tianjin, Tianjin, China

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions: Drug: Vincristine
Drug: Daunorubicin
Drug: Cyclophosphamide
Drug: Pegaspargase
Drug: Prednisone
Drug: Cytarabine
Drug: 6-mercaptopurine
Drug: Dexamethasone
Drug: Methotrexate
Drug: Venetoclax

First Posted Date: 2022-12-21

Last Posted Date: 2023-03-03

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 100

Registration Number: NCT05660473

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

Phase 2

Completed

Conditions: Untreated
Non Severe Aplastic Anemia

Interventions: Drug: Herombopag

First Posted Date: 2022-12-21

Last Posted Date: 2025-01-30

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 54

Registration Number: NCT05660785

Locations: 🇨🇳
Tangshan Central Hospital, Tangshan, Hebei, China
🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China
🇨🇳
The Second Affilated Hospital of Shandong First Medical University, Tai'an, Shandong, China

and more 1 locations

CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Biological: LCAR-AMDR Cells Product

First Posted Date: 2022-12-16

Last Posted Date: 2023-12-13

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 4

Registration Number: NCT05654779

Locations: 🇨🇳
Beijing Gobroad BoRen Hospital, Beijing, Beijing, China
🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China

A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients

Phase 1

Recruiting

Conditions: Hemophilia B

Interventions: Genetic: ZS801

First Posted Date: 2022-12-07

Last Posted Date: 2025-02-24

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 21

Registration Number: NCT05641610

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.

Not Applicable

Recruiting

Conditions: Hemophilia B

Interventions: Genetic: ZS801

First Posted Date: 2022-11-30

Last Posted Date: 2025-02-24

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 6

Registration Number: NCT05630651

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Procedure: Autologous hematopoietic stem cell transplantation
Biological: C-CAR088

First Posted Date: 2022-11-30

Last Posted Date: 2022-11-30

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 20

Registration Number: NCT05632380

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

Not Applicable

Not yet recruiting

Conditions: Bone Marrow Transplant
Ph+ ALL
Minimal Residual Disease

Interventions: Drug: the usage of Olverembatinib combined with Inotuzumab Ozogamicin

First Posted Date: 2022-11-02

Last Posted Date: 2022-11-02

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 46

Registration Number: NCT05603156

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy